Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on March 17, 2021. The report primarily addresses the closing of a merger transaction that occurred on March 9, 2021, and the subsequent capital structure of the company.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative financial metric disclosed is the post-merger share count.
- Common Stock Outstanding: 383,179,376 shares as of the merger closing on March 9, 2021.
- Trading Symbol: IBRX (Nasdaq Global Select Market).
Material Changes
The material change reported is the completion of a merger transaction on March 9, 2021. This event resulted in the establishment of the current outstanding share count of 383,179,376 shares. No other material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing references an investor presentation (Exhibit 99.1) intended to provide further details on the company's outlook. However, the text of this 8-K explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. Consequently, specific guidance, management commentary, risks, or contingencies are not contained within the body of this report.
Investor Verification Checklist
- Verify the details of the merger transaction closed on March 9, 2021, by reviewing the referenced Exhibit 99.1 (Investor Presentation).
- Confirm the current share count of 383,179,376 against subsequent filings to account for any post-closing adjustments.
- Review the company's most recent 10-K or 10-Q for detailed financial statements, as this 8-K does not contain revenue or cash flow data.